Found 3 articles for: "type 2 diabetes mellitus"
The Safety of GLP1 Receptor Agonist Usage in Mohs Micrographic Surgery Patients
April 2026 | Volume 25 | Issue 4 | Editorials | 394 | Copyright © April 2026
Glucagon-Like Peptide-1 Receptor Agonists Reduce Surgeries and Hospitalizations in Hidradenitis Suppurativa: A Multicenter TriNetX Cohort Study
September 2025 | Volume 24 | Issue 9 | Original Article | 869 | Copyright © September 2025
Background: Hidradenitis suppurativa is a chronic inflammatory skin condition frequently associated with type 2 diabetes mellitus and obesity. Glucagon-like peptide-1 receptor ag...
Read MoreA Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies
April 2025 | Volume 24 | Issue 4 | Features | 413 | Copyright © April 2025
Glucagon-like peptide-1 (GLP-1) agonists are used to treat type 2 diabetes mellitus (T2DM) and have recently gained approval and popularity for treating obesity and weight loss. There is a lack o...
Read More
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.